After signing up, you'll start to receive regular news updates from us.
DxS and Amgen Enter into Collaboration to Provide a K-RAS Companion Diagnostic for Vectibix® in the United States
Complete the form below to unlock access to ALL audio articles.
DxS has signed an agreement with Amgen Inc. to provide a K-RAS companion diagnostic for Vectibix® (panitumumab) in the United States.
Pursuant to the terms of the agreement, DxS and Amgen shall work together to further facilitate the use of Vectibix® in metastatic colorectal cancer patients with wild-type K-RAS status in the United States, with the intent that DxS’ TheraScreen: K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix® if approved by the FDA.
This agreement between Amgen and DxS follows a collaboration entered into by the parties last year with respect to the TheraScreen: K-RAS Mutation Kit in Europe.
Dr Stephen Little, CEO of DxS said: “We are very pleased to be working with Amgen and building on our relationship. We believe that this agreement is a further endorsement of the capabilities of our K-RAS diagnostic test. We look forward to working with Amgen and the FDA to ensure that colorectal cancer patients in the USA have access to a K-RAS diagnostic test kit.”
Financial terms of the agreement are not disclosed.
